10-Q Filing

INSIGHT MOLECULAR DIAGNOSTICS INC. CIK: 1642380 Q1 2022

Filing Information

Form Type	10-Q
Accession Number	`0001493152-22-013051`
Period End Date	20220331
Filing Date	20220512
Fiscal Year	2022
Fiscal Period	Q1
XBRL Instance	form10-q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 78 Income Statement 40 Cash Flow Statement 76 Stockholders Equity 20 Comprehensive Income 6

Balance Sheet 78 line items

Line Item	Tag	Value	Unit	Period
Preferred stock no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Preferred stock no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$20.41M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$35.60M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$2.12M	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$1.44M	USD	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$904.00K	USD	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$574.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.51M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.20M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	230.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	230.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$24.62M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	92.23M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$39.14M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	92.25M	shares	Point-in-time
Common stock, shares, outstanding	`CommonStockSharesOutstanding`	92.25M	shares	Point-in-time
Common stock, shares, outstanding	`CommonStockSharesOutstanding`	92.23M	shares	Point-in-time
Right-of-use and financing lease assets, net	`FinanceLeaseRightOfUseAsset`	$2.78M	USD	Point-in-time
Right-of-use and financing lease assets, net	`FinanceLeaseRightOfUseAsset`	$2.64M	USD	Point-in-time
Machinery and equipment, net, and construction in progress	`MachineryAndEquipmentNetAndConstructionInProgress`	$8.02M	USD	Point-in-time
Machinery and equipment, net, and construction in progress	`MachineryAndEquipmentNetAndConstructionInProgress`	$5.75M	USD	Point-in-time
Goodwill	`Goodwill`	$18.68M	USD	Point-in-time
Goodwill	`Goodwill`	$18.68M	USD	Point-in-time
Goodwill	`Goodwill`	$9.19M	USD	Point-in-time
Goodwill	`Goodwill`	$9.49M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$90.32M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$91.25M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$1.70M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$1.70M	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$298.00K	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$264.00K	USD	Point-in-time
TOTAL ASSETS	`Assets`	$146.27M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$159.56M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$2.58M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$2.45M	USD	Point-in-time
Accrued compensation	`AccruedLiabilitiesCurrent`	$3.38M	USD	Point-in-time
Accrued compensation	`AccruedLiabilitiesCurrent`	$3.38M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$2.42M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$3.26M	USD	Point-in-time
Accrued severance from acquisition, current	`AccruedSeveranceFromAcquisitionCurrent`	$2.32M	USD	Point-in-time
Accrued severance from acquisition, current	`AccruedSeveranceFromAcquisitionCurrent`	$2.35M	USD	Point-in-time
Accrued liabilities from acquisition, current	`BusinessCombinationContingentConsiderationLiabilityCurrent`	$1.39M	USD	Point-in-time
Accrued liabilities from acquisition, current	`BusinessCombinationContingentConsiderationLiabilityCurrent`	$624.00K	USD	Point-in-time
Loans payable, net of deferred financing costs, current	`LoansPayableCurrent`	$945.00K	USD	Point-in-time
Loans payable, net of deferred financing costs, current	`LoansPayableCurrent`	$1.31M	USD	Point-in-time
Right-of-use and financing lease liabilities, current	`OperatingLeaseAndFinancingLeaseLiabilitiesCurrent`	$850.00K	USD	Point-in-time
Right-of-use and financing lease liabilities, current	`OperatingLeaseAndFinancingLeaseLiabilitiesCurrent`	$819.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$14.12M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$13.96M	USD	Point-in-time
Right-of-use and financing lease liabilities, noncurrent	`OperatingLeaseLiabilitiesAndFinancingLeaseLiabilitiesNonCurrent`	$3.54M	USD	Point-in-time
Right-of-use and financing lease liabilities, noncurrent	`OperatingLeaseLiabilitiesAndFinancingLeaseLiabilitiesNonCurrent`	$3.33M	USD	Point-in-time
Contingent consideration liabilities	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$76.68M	USD	Point-in-time
Contingent consideration liabilities	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$72.03M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$94.35M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$89.31M	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, no par value, 230,000 shares authorized; 92,247 and 92,232 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	`CommonStockValue`	$254.99M	USD	Point-in-time
Common stock, no par value, 230,000 shares authorized; 92,247 and 92,232 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	`CommonStockValue`	$252.95M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$38.00K	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$37.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-187.77M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-198.06M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$106.63M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$33.48M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$56.97M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$65.22M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$146.27M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$159.56M	USD	Point-in-time

Income Statement 40 line items

Line Item	Tag	Value	Unit	Period
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$1.42M	USD	1 Quarter
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$1.12M	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	$1.02M	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	$738.00K	USD	1 Quarter
Cost of revenues amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	$307.00K	USD	1 Quarter
Cost of revenues amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	$936.00K	USD	1 Quarter
Gross profit	`GrossProfit`	$79.00K	USD	1 Quarter
Gross profit	`GrossProfit`	$-533.00K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$3.36M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$5.13M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$3.24M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$2.25M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$4.76M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$5.65M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-4.66M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$1.06M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$11.44M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$9.36M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-11.36M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-9.89M	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNet`	$-68.00K	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNet`	$-30.00K	USD	1 Quarter
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-330.00K	USD	1 Quarter
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$213.00K	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-270.00K	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	-	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$2.00K	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-36.00K	USD	1 Quarter
Total other expenses, net	`NonoperatingIncomeExpense`	$-123.00K	USD	1 Quarter
Total other expenses, net	`NonoperatingIncomeExpense`	$-396.00K	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-10.29M	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-11.48M	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	$-7.56M	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-10.29M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-3.92M	USD	1 Quarter
Net loss per share: basic and diluted	`EarningsPerShareBasic`	$-0.11	USD	1 Quarter
Net loss per share: basic and diluted	`EarningsPerShareBasic`	$-0.05	USD	1 Quarter
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfSharesOutstandingBasic`	82.12M	shares	1 Quarter
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfSharesOutstandingBasic`	92.24M	shares	1 Quarter

Cash Flow Statement 76 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-10.29M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-3.92M	USD	1 Quarter
Depreciation expense	`Depreciation`	$121.00K	USD	1 Quarter
Depreciation expense	`Depreciation`	$287.00K	USD	1 Quarter
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$307.00K	USD	1 Quarter
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$928.00K	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-270.00K	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	-	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$1.29M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$2.01M	USD	1 Quarter
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-330.00K	USD	1 Quarter
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$213.00K	USD	1 Quarter
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$7.00K	USD	1 Quarter
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$19.00K	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-4.66M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$1.06M	USD	1 Quarter
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	-	USD	1 Quarter
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-7.56M	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$499.00K	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$685.00K	USD	1 Quarter
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$25.00K	USD	1 Quarter
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-35.00K	USD	1 Quarter
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$1.14M	USD	1 Quarter
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$351.00K	USD	1 Quarter
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$405.00K	USD	1 Quarter
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-21.00K	USD	1 Quarter
Accrued severance and liabilities from Chronix Biomedical acquisition	`AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition`	$800.00K	USD	1 Quarter
Accrued severance and liabilities from Chronix Biomedical acquisition	`AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition`	-	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-9.84M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-13.28M	USD	1 Quarter
Acquisition of Insight Genetics, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	-	USD	1 Quarter
Acquisition of Insight Genetics, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$607.00K	USD	1 Quarter
Acquisition of Razor Genomics asset, net of cash acquired	`AcquisitionOfRazorGenomicsAssetNetOfCashAcquired`	-	USD	1 Quarter
Acquisition of Razor Genomics asset, net of cash acquired	`AcquisitionOfRazorGenomicsAssetNetOfCashAcquired`	$6.65M	USD	1 Quarter
Acquisition of Chronix Biomedical, net of cash acquired	`AcquisitionOfChronixBiomedicalNetOfCashAcquired`	-	USD	1 Quarter
Acquisition of Chronix Biomedical, net of cash acquired	`AcquisitionOfChronixBiomedicalNetOfCashAcquired`	$175.00K	USD	1 Quarter
Construction in progress and purchases of furniture and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$842.00K	USD	1 Quarter
Construction in progress and purchases of furniture and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.56M	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-8.27M	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.56M	USD	1 Quarter
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$348.00K	USD	1 Quarter
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	-	USD	1 Quarter
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	$65.26M	USD	1 Quarter
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	-	USD	1 Quarter
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	-	USD	1 Quarter
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	$2.68M	USD	1 Quarter
Proceeds from sale of common shares under at-the-market transactions	`ProceedsFromIssuanceOfPrivatePlacement`	$31.00K	USD	1 Quarter
Proceeds from sale of common shares under at-the-market transactions	`ProceedsFromIssuanceOfPrivatePlacement`	$6.75M	USD	1 Quarter
Financing costs for at-the-market sales	`PaymentForFinancingCostsForAtthemarketSales`	$203.00K	USD	1 Quarter
Financing costs for at-the-market sales	`PaymentForFinancingCostsForAtthemarketSales`	$1.00K	USD	1 Quarter
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$802.00K	USD	1 Quarter
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	1 Quarter
Repayment of loan payable	`RepaymentsOfDebt`	$375.00K	USD	1 Quarter
Repayment of loan payable	`RepaymentsOfDebt`	$375.00K	USD	1 Quarter
Repayment of financing lease obligations	`RepaymentOfFinancingLeaseObligations`	$10.00K	USD	1 Quarter
Repayment of financing lease obligations	`RepaymentOfFinancingLeaseObligations`	$41.00K	USD	1 Quarter
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$69.87M	USD	1 Quarter
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-355.00K	USD	1 Quarter
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$51.76M	USD	1 Quarter
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-15.19M	USD	1 Quarter
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$37.30M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.84M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$60.61M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$22.11M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$37.30M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.84M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$60.61M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$22.11M	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	$44.00K	USD	1 Quarter
Cash paid for interest	`InterestPaidNet`	$13.00K	USD	1 Quarter
Common stock issued for acquisition of Razor Genomics asset	`StockIssued1`	$5.76M	USD	1 Quarter
Common stock issued for acquisition of Razor Genomics asset	`StockIssued1`	-	USD	1 Quarter
Deferred tax liability generated from the acquisition of Razor Genomics asset	`DeferredTaxLiabilityGeneratedFromAcquisitionOfRazorGenomicsAsset`	-	USD	1 Quarter
Deferred tax liability generated from the acquisition of Razor Genomics asset	`DeferredTaxLiabilityGeneratedFromAcquisitionOfRazorGenomicsAsset`	$7.56M	USD	1 Quarter
Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability	`ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability`	$139.00K	USD	1 Quarter
Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability	`ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability`	$993.00K	USD	1 Quarter

Stockholders Equity 20 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, value	`StockholdersEquity`	$106.63M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$33.48M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$56.97M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$65.22M	USD	Point-in-time
Net Loss	`NetIncomeLoss`	$-10.29M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-3.92M	USD	1 Quarter
Foreign currency translation adjustment	`AdjustmentstoForeignCurrencyTranslation`	$1.00K	USD	1 Quarter
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$1.29M	USD	1 Quarter
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$2.01M	USD	1 Quarter
Sale of common shares, including at-the-market transactions	`StockIssuedDuringPeriodValueOfSaleOfCommonSharesUnderAtthemarketTransactions`	$71.75M	USD	1 Quarter
Sale of common shares, including at-the-market transactions	`StockIssuedDuringPeriodValueOfSaleOfCommonSharesUnderAtthemarketTransactions`	$31.00K	USD	1 Quarter
Financing costs paid to issue common shares, including at-the-market transactions	`StockIssuedDuringPeriodValueOther`	$-2.88M	USD	1 Quarter
Financing costs paid to issue common shares, including at-the-market transactions	`StockIssuedDuringPeriodValueOther`	$-1.00K	USD	1 Quarter
Stock options exercised	`StockIssuedDuringPeriodValueStockOptionsExercised`	$348.00K	USD	1 Quarter
Warrants exercised	`StockIssuedDuringPeriodValueWarrantsExercised`	$802.00K	USD	1 Quarter
Issuance of common stock to Razor Genomics	`StockIssuedDuringPeriodValueAcquisitions`	$5.76M	USD	1 Quarter
Ending balance, value	`StockholdersEquity`	$106.63M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$33.48M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$56.97M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$65.22M	USD	Point-in-time

Comprehensive Income 6 line items

Line Item	Tag	Value	Unit	Period
NET LOSS	`NetIncomeLoss`	$-10.29M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-3.92M	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	-	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$1.00K	USD	1 Quarter
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-10.29M	USD	1 Quarter
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-3.92M	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.